The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
284
NBI-1117568 will be administered per schedule specified in the arm description.
Placebo will be administered per schedule specified in the arm description.
Neurocrine Clinical Site
Little Rock, Arkansas, United States
RECRUITINGChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
Time frame: Baseline, Week 5
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 5
Time frame: Baseline, Week 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Culver City, California, United States
RECRUITINGNeurocrine Clinical Site
Garden Grove, California, United States
RECRUITINGNeurocrine Clinical Site
Riverside, California, United States
RECRUITINGNeurocrine Clinical Site
Hollywood, Florida, United States
RECRUITINGNeurocrine Clinical Site
Atlanta, Georgia, United States
COMPLETEDNeurocrine Clinical Site
North Canton, Ohio, United States
RECRUITINGNeurocrine Clinical Site
Pleven, Bulgaria
RECRUITINGNeurocrine Clinical Site
Sliven, Bulgaria
RECRUITINGNeurocrine Clinical Site
Veliko Tarnovo, Bulgaria
WITHDRAWN...and 10 more locations